NCT02953782 - Study of Magrolimab (Hu5F9-G4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 2, 2016

Primary Completion Date

February 10, 2020

Study Completion Date

February 10, 2020

Conditions

Solid TumorColorectal Cancer

Interventions

DRUG

Magrolimab

Administered intravenously

DRUG

Cetuximab

Administered intravenously

Trial Locations (8)

UPENN, Philadelphia

Sarah Cannon Research Institute, Nashville

Wayne State University, Detroit

START Midwest, Grand Rapids

Md Anderson, Houston

START Center for Cancer Care, San Antonio

UCLA, Los Angeles

Stanford University, Palo Alto